Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.

Saved in:
Bibliographic Details
Title: Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.
Authors: O'Hara MH; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania., Jegede O; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts., Dickson MA; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York., DeMichele AM; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania., Piekarz R; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Gray RJ; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts., Wang V; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Patton DR; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, Maryland., Hamilton SR; City of Hope National Medical Center, Duarte, California., Onitilo A; Marshfield Medical Center - Weston, Weston, Wisconsin., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Arteaga CL; UT Southwestern Simmons Cancer Center, Dallas, Texas., Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., O'Dwyer PJ; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania., Chen AP; Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, National Cancer Institute, Bethesda, Maryland., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Jan 06; Vol. 31 (1), pp. 56-64.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Be the first to leave a comment!
You must be logged in first